Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVE: Almonertinib in Advanced NSCLC Patients Intolerant to Osimertinib
NCT04882345Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04882345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882345.